Citations 3
Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder
Pittock, Sean J. , Barnett, Michael , Bennett, Jeffrey L. , Berthele, Achim , Sèze, Jérôme de, Levy, Michael , Nakashima, Ichiro , Oreja‐Guevara, Celia , Palace, Jacqueline , Paul, Friedemann , Pathak, Ritu, Allen, Kerstin, Parks, Becky, Kim, Ho Jin , Pittock, S J , Barnett, Michael H , Pozzilli, Carlo , Kim, Ho Jin , Bennett, Jeffrey L , Levy, Michael , Oreja-Guevara, Celia , Nakashima, Ichiro , Paul, Friedemann , Palace, Jacqueline , Seze, Jerome De , Pozzilli, Carlo , Pathak, Ritu, Allen, Kerstin , Parks, Becky
Neurology Neuroimmunology & Neuroinflammation | July 13, 2026 | Volume: 13 | Issue: 5 | Pages: No page available
Gene Expression Signatures Associated with Prior Rituximab Treatment in Patients with Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) in the CHAMPION-NMOSD Trial (S6.007)
Pittock, Sean, Çelen, İrem, Allen, Kerstin, Case, Dan, Bou-Chahine, Ruba, Pittock, Sean J. , Allen, Kerstin , Bou-Chahine, Ruba
Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available
Long-term Efficacy and Safety of Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Final Analysis of the Phase 3 CHAMPION-NMOSD Trial (P7-1.012)
Pittock, Sean, Barnett, Michael, Bennett, Jeffrey, Berthele, Achim, Seze, Jérôme de, Levy, Michael, Oreja-Guevara, Celia, Palace, Jacqueline, Paul, Friedemann, Allen, Kerstin, Parks, Becky, Kim, Ho Jin, Pittock, Sean J. , Barnett, Michael , Bennett, Jeffrey, Berthele, Achim , Seze, Jerome De , Levy, Michael , Nakashima, Ichiro , Oreja‐Guevara, Celia , Palace, Jacqueline , Paul, Friedemann , Pozzilli, Carlo , Allen, Kerstin , Parks, Becky , Kim, Ho Jin
Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available